U.S. Markets open in 38 mins.


ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.0050.000 (0.000%)
At close: 4:10PM AEST
Full screen
Previous Close0.005
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.005 - 0.006
52 Week Range0.005 - 0.006
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.20
  • PR Newswire4 months ago

    Unilife Files for Chapter 11 Protection

    ASX: UNS) today announced that it has commenced a formal proceeding to restructure its balance sheet or to sell its assets as a going concern in order to better position the business for the future.  To facilitate this restructuring or sale, the Company filed voluntary petitions under chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the "Court").  Unilife's foreign affiliates in Australia are not included in the filing but are expected to be included in the restructuring or sale.  Unilife's operations will remain ongoing during the chapter 11 process. The Company has obtained a commitment for a $7 million debtor-in-possession ("DIP") financing facility underwritten by an affiliate of OrbiMed Advisors.  Subject to Court approval, this DIP financing, combined with the Company's cash from operations, is expected to provide sufficient liquidity during the chapter 11 cases to support the company's continuing business operations and minimize disruption.

  • Associated Press6 months ago

    Unilife reports 2Q loss

    The York, Pennsylvania-based company said it had a loss of 92 cents per share. The medical device maker posted revenue of $2.3 million in the period. The company's shares closed at $2.28. A year ago, they ...

  • PR Newswire6 months ago

    Lifshitz & Miller LLP Announces Investigation of Anthera Pharmaceuticals, Inc., Arctic Cat Inc., Banc of California, Inc., Dollar General Corporation, MoneyGram International, Inc., QUALCOMM Incorporated, Stonegate Mortgage Corporation and Unilife Corporation

    NEW YORK, Feb. 3, 2017 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (ANTH) Lifshitz & Miller announces investigation on behalf of ANTH investors concerning the development of CHABLIS-SC1 and liprotamase ...